PDF icon Download PDF
Facial Plast Surg
DOI: 10.1055/a-2697-3263
Original Research

The Role of Triamcinolone in Postrhinoplasty Recovery: A Systematic Review

Pedro Pablo Villarroel 
1   Department of Otolaryngology, Rhinology Unit, Hospital Universitario de Poniente, Almería, Spain
,
Marcelo Davila
1   Department of Otolaryngology, Rhinology Unit, Hospital Universitario de Poniente, Almería, Spain
,
Maria Jesus Sanchez
2   Department of Oral and Maxillofacial Surgery, Hospital Universitario Virgen de las Nieves, Granada, Spain
,
Cristobal Langdon
3   Department of Otolaryngology, Rhinology and Skull Base Unit, Hospital Sant Joan de Déu, Barcelona, Spain
,
Diego Arancibia-Tagle
4   Facial Plastic Surgery, Private Practice, Mallorca, Spain
› Author Affiliations
› Further Information
Also available atMedOne
   Permissions and Reprints
Preview

Abstract

Introduction

Postoperative edema and fibrosis are key concerns following rhinoplasty, affecting outcomes and patient satisfaction. Triamcinolone acetonide (TA) is used for its proven anti-inflammatory and antifibrotic effects.

Objective

This study aims to evaluate the efficacy, usage profile, and safety of TA injections after rhinoplasty, focusing on postoperative edema and supratip fullness.

Methods

A systematic review was conducted via PubMed and the Cochrane Database to identify studies on corticosteroid injections after rhinoplasty, following PRISMA guidelines and predefined selection criteria.

Results

Nine studies were included in the analysis. These studies focused on the postoperative use of TA after rhinoplasty and assessed their impact on key outcomes, such as edema reduction, fibrosis control, and the improvement of supratip fullness following rhinoplasty.

Discussion

TA injections were consistently associated with a significant reduction in postoperative edema and the incidence of pollybeak deformities. Current evidence supports the subcutaneous administration of TA at a 10 mg/mL concentration, initiated no earlier than 4 weeks following rhinoplasty. Injections are typically delivered at 4 to 6 week intervals, with a maximum volume of 0.3 mL per session, for a total of two to four administrations, depending on clinical response. TA showed a consistent safety profile with mild and infrequent side effects. Effects appeared within 7 to 14 days and lasted approximately 4 to 6 weeks.

Conclusion

TA is an effective adjunct in the postoperative management of rhinoplasty, particularly in patients with thick or reactive soft tissue envelopes. Standardized, personalized protocols are needed, along with better studies and objective outcome tools.

Keywords

triamcinolone acetonide and rhinoplasty - postoperative edema and rhinoplasty - corticosteroid injection in rhinoplasty


Publication History

Received: 04 August 2025

Accepted: 06 September 2025

Accepted Manuscript online:
08 September 2025

Article published online:
12 September 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA